ScholarIQanswers from OpenAlex
Clovis Oncology
FunderResearch funding and supported work
Clovis Oncology is a funder indexed in ScholarIQ from OpenAlex.
What is known about Clovis Oncology?
ScholarIQrecord summary
company in Boulder, United States
How many works does Clovis Oncology have?
ScholarIQindexed works
Clovis Oncology has 1,239 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Clovis Oncology?
ScholarIQopenalex
The OpenAlex for Clovis Oncology is on the source record.
What is the ROR of Clovis Oncology?
ScholarIQror
The ROR for Clovis Oncology is on the source record.
What are the most-cited papers on Clovis Oncology?
ScholarIQmost cited works
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, René dePont Christensen, Whitney A. Spannuth Graybill, Mansoor R. Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, К. Jardon, Andrés Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O’Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley Haggerty, María Jesús Rubio-Pérez, Mark S. Shahin, Giorgia Mangili, William H. Bradley, Ilan Bruchim, Kaiming Sun, Izabela A. Malinowska, Yong Li, Divya Gupta, Bradley J. Monk
<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux, Scott Gettinger, Grainne M. O’Kane, Kathryn C. Arbour, Joel W. Neal, Hatim Husain, Tracey L. Evans, Julie R. Brahmer, Alona Muzikansky, Philip Bonomi, Salvatore Del Prete, Anna Wurtz, Anna F. Farago, Dora Dias‐Santagata, Mari Mino–Kenudson, Karen L. Reckamp, Helena A. Yu, Heather A. Wakelee, Frances A. Shepherd, Zofia Piotrowska, Lecia V. Sequist
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B.J. Monk, Maria Pilar Barretina-Ginesta, Bhavana Pothuri, Ignace Vergote, Whitney A. Spannuth Graybill, Mansoor Raza Mirza, C. C. McCormick, Domenica Lorusso, Richard G. Moore, Gilles Freyer, Roisin E. O’Cearbhaill, Florian Heitz, David M. O’Malley, Andrés Redondo, Mark S. Shahin, Christof Vulsteke, William H. Bradley, Charlotte Aaquist Haslund, Dana M. Chase, Carmela Pisano, L.L. Holman, M.J. Rubio Pérez, Paul DiSilvestro, Lydia Gaba, Thomas J. Herzog, Ilan Bruchim, Natalie Compton, L. Shtessel, Izabela A. Malinowska, Antonio González-Martı́n
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, Whitney S. Graybill, Ana Beatriz Sánchez, Colleen McCormick, Jean‐François Baurain, Anna V. Tinker, Hannelore Denys, Roisin E. O’Cearbhaill, Sakari Hietanen, Richard G. Moore, Anja Ør Knudsen, Thibault de La Motte Rouge, Florian Heitz, Tally Levy, Whitney York, Divya Gupta, Bradley J. Monk, Antonio González-Martı́n
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study
Rebecca Kristeleit, S. Ghamande, Alla Lisyanskaya, A. Oaknin, Emily Prendergast, Y.B. Kim, José Fuentes Pradera, Ramey D. Littell, Bo Gao, G. Valabrega, David M. O’Malley, Andrew Dean, C. Pisano, J. Buscema, D. Provencher, Flora Zagouri, Lainie P. Martin, Hung‐Hsueh Chou, Fuat Demirkıran, F. Ueland, Anita Chudecka-Głaz, Oladapo Yeku, Mario Beiner, Charles Anderson, Vít Drochýtek, Ramez N. Eskander, R. Agarwal, Lara Maloney, Darrin Despain, Carol S. Connor, Marcia Craib, Danny Shih, K. Fujiwara, B.J. Monk